Everus Construction Group, Inc. (ECG) Stock Analysis

82.0/100
Strong Buy Not Halal Industrials
Price $85.25
Market Cap $4.35B
52-Week Change -6.91%

Is ECG a good investment?

Everus Construction Group, Inc. (ECG) has a Plutrex AI rating of 82.0/100 as of November 13, 2026, indicating a Strong Buy consensus. The stock is not classified as halal-compliant. Key strength: ROE of 40.3% is 121.8% above the industry average of 18.16%, achieved with LESS leverage (D/E 0.74 vs. industry 0.855) — this is the hallmark of genuine operational superiority, not financial engineering; FCF of $237.4M validates earnings quality with near 1:1 FCF-to-cash ratio. Main concern: Near-term EPS growth of 12.35% next year is 54.6% below industry average of 27.24%, and the 19.3% price decline since prior report ($108.06 → $87.17) with analyst target cut from $176.00 to $153.50 (-12.8%) signals the market is repricing growth expectations downward; if next-year growth remains depressed, the bridge to 26.29% 5-year CAGR requires significant re-acceleration in years 2-5 that must be validated.

Investment Summary

ECG (Everus Construction Group) is an Engineering & Construction industry leader trading at a severe valuation discount following a 19.3% price decline since the prior report ($108.06 → $87.17), with no corresponding deterioration in fundamentals — in fact, fundamentals have improved. The stock now trades at P/E of 15.38x (vs. industry 31.28x, a 50.8% discount) with a PEG of 0.59 (vs. industry 3.65, an 83.9% discount) against 5-year EPS growth of 26.3%. ROE of 40.3% is 121.8% above the industry average of 18.16%, achieved with moderate D/E of 0.74 (below industry 0.855). FCF of $237.4M nearly matches the $245.1M cash balance, confirming earnings quality. Revenue growth accelerated to 40.3% (from 33.7% prior period) and earnings growth of 61.3% demonstrates powerful operating leverage. The analyst consensus target has been revised from $176.00 to $153.50, but the implied upside from $87.17 is 76.1% — arguably more achievable. The key current concern remains the near-term EPS growth deceleration to 12.35% next year vs. industry 27.24%, but the Q3 earnings beat and raised 2026 guidance ('Everus Reports Third Quarter 2026 Results, Raises 2026 Guidance') directly address this worry. News sentiment of 93.9/100 with zero negative articles reinforces the thesis. This is a fundamentals-dominant situation — the price drop is an opportunity, not a warning.

Key Strengths

Key Concerns

Plutrex 10-Factor AI Breakdown

Financial Health
82/100
Growth Potential
78/100
Valuation
92/100
Profitability
65/100
Debt Management
85/100
Analyst Sentiment
80/100
Technical Momentum
48/100
Insider Confidence
72/100
News Sentiment
94/100

Fundamental Analysis

ECG presents compelling fundamentals at an increasingly attractive price point. Profitability: Gross margin of 13.4% is thin (below industry 15.5%) reflecting the capital-intensive E&C business model, but operating margin of 8.2% (vs. industry 7.92%) and net margin of 6.2% (vs. industry 3.93%, a 57.9% premium) show ECG manages costs effectively below the gross line. ROE of 40.3% is the standout — more than double the industry average of 18.16% and achieved with less leverage than peers (D/E 0.74 vs. 0.855), confirming genuine operational excellence. Valuation: P/E of 15.38x is at a 50.8% discount to industry peers at 31.28x. PEG of 0.59 compares to industry 3.65 — ECG is priced at 59 cents per growth unit vs. $3.65 for peers, an 83.9% discount. This is the single most compelling signal in the entire analysis. Growth: Revenue growth accelerated to 40.3% (vs. 33.7% prior period, +19.6% improvement), earnings growth 61.3% — both above industry averages. Near-term deceleration to 12.35% next-year EPS growth is the primary concern (vs. industry 27.24%), but 5-year EPS CAGR of 26.29% essentially matches industry 25.17%, confirming this is a transitory trough not structural decay. Health: FCF of $237.4M nearly equals total cash of $245.1M — exceptional cash conversion. D/E of 0.74 provides financial flexibility below industry norm.

News Sentiment

Everus Construction Group is quietly doing something remarkable: delivering stellar financial results while its stock price tells a completely different story. The company just crushed third-quarter 2026 expectations and immediately raised its full-year guidance — the kind of double-beat that typically sends stocks soaring. Yet shares have dropped roughly 15% over the past three months, creating what analysts are calling a rare disconnect between business performance and market price. According to the Q3 2026 Earnings Call Transcript and Everus Reports Third Quarter 2026 Results headlines, the company isn't just surviving — it's thriving across multiple fronts. The growth engine isn't a one-trick pony dependent on a single hot sector. While data centers are certainly powering revenue, the ECG Q3 Earnings Call Highlights confirm broad-based expansion spanning multiple markets, with a record backlog signaling the pipeline of future work has never been stronger. This diversification is crucial: it means the company isn't betting everything on one technology trend. The Q3 Earnings and Revenues Beat Estimates headline underscores that management isn't just promising results — they're delivering them. For everyday investors, the story is straightforward: a construction company that builds the infrastructure powering America's digital economy is growing fast, generating real cash, and trading at half the price-to-earnings ratio of its competitors. The question isn't whether Everus is a good business. The question is whether the stock's recent weakness is a warning sign or a window of opportunity.

Risk Assessment

PRIMARY RISK: Continued technical deterioration. The stock has fallen 15% over three months and another 19.3% since the prior report — a persistent downtrend that could have further momentum before stabilizing. The analyst target was cut from $176.00 to $153.50, suggesting institutional reassessment of growth expectations. SECONDARY RISK: Near-term EPS growth deceleration to 12.35% (vs. industry 27.24%) could keep the stock range-bound near-term if the market focuses on 1-year metrics rather than 5-year CAGR of 26.29%. TERTIARY RISK: Thin gross margin of 13.4% creates earnings sensitivity to cost inflation. MITIGATION: The stop at $76.00 (-12.2% from $86.50 entry midpoint) limits downside to ~$10.50 per share vs. $67.00 potential upside to analyst target — a 6.3:1 reward-to-risk ratio. Position sizing at 4% reflects high-quality conviction offset by ongoing technical weakness. The Q3 earnings beat and raised guidance provide a potential catalyst for trend reversal. Fundamental floor: at $76.00, P/E would be approximately 12.1x — extremely difficult to justify further compression for a business with 40.3% ROE and 26.3% 5-year EPS growth.

Related Halal Stocks

Related Stocks

Frequently Asked Questions

Is ECG a halal stock?

No, Everus Construction Group, Inc. (ECG) is currently not classified as halal by AAOIFI criteria.

What is Plutrex's AI rating for ECG?

Everus Construction Group, Inc. (ECG) has a Plutrex AI rating of 82.0/100 with a Strong Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.

Is ECG a good investment?

According to Plutrex AI, ECG has a Strong Buy rating (82.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.

How can I invest in ECG?

US stocks like ECG can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. ElBarake provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.

What are the main risks of investing in ECG?

Plutrex AI identifies the main risks for ECG by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.

Chat with ElBarake AI about ECG

Ask anything about this stock and get an instant AI-powered answer — free, no signup required.

Open ECG in ElBarake